Rue du Bois Saint Jean 15/1
BCE / VAT: BE 0521.816.349
Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins to improve microbial fermentation.
Our team of scientists works in different academic laboratories and our R&D programs involve partners from Belgium, Brazil, France, Germany, The Netherlands, and the UK. We think of ourselves as a “Startup in the Labs”, meaning that we work directly in the labs of our academic partners.
The members of our Scientific Advisory Board are active in Belgium, France and the USA.
genetic technologies that make microbial strains
involved in industrial processes safer and more efficient.
Bacteriocins are ribosomally-produced, genetically encoded antimicrobial peptides produced by a wide variety of microorganisms.
The history of bacteriocins begins with André Gratia in Belgium in 1925, concurrent with the discovery of antibiotics and bacteriophages.
With synthetic biology, it is now possible to revisit the code of bacteriocins in order to modify the spectrum of action and even make entirely new bacteriocins.
In Bacteriocins vs Antibiotics and Bacteriophages, the advantages of bacteriocins are described in the context of rising AMR (Antimicrobial resistance).
Syngulon is building a collection of natural and synthetic bacteriocins.
Syngulon offers a new selection technology focused on the control of microorganismal growth. This technology is based on the use of bacteriocin/immunity in any bacteria, yeast or algae for controlled growth of microorganisms (US Patent 9,333,227).
Syngulon has demonstrated its selection technology’s efficacy at lab scale and is working with customers to use this technology for the production of recombinant products (application in sterile condition).
For application in open or semi-open fermentor, Syngulon can customize the bacteriocins based on metagenomic analysis of contaminants.